These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35983955)

  • 21. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling.
    Wang B; Jie Z; Joo D; Ordureau A; Liu P; Gan W; Guo J; Zhang J; North BJ; Dai X; Cheng X; Bian X; Zhang L; Harper JW; Sun SC; Wei W
    Nature; 2017 May; 545(7654):365-369. PubMed ID: 28489822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapamycin reverses insulin resistance (IR) in high-glucose medium without causing IR in normoglycemic medium.
    Leontieva OV; Demidenko ZN; Blagosklonny MV
    Cell Death Dis; 2014 May; 5(5):e1214. PubMed ID: 24810050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity.
    Lamming DW; Ye L; Katajisto P; Goncalves MD; Saitoh M; Stevens DM; Davis JG; Salmon AB; Richardson A; Ahima RS; Guertin DA; Sabatini DM; Baur JA
    Science; 2012 Mar; 335(6076):1638-43. PubMed ID: 22461615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Mammalian Target of Rapamycin (mTOR) in Insulin Signaling.
    Yoon MS
    Nutrients; 2017 Oct; 9(11):. PubMed ID: 29077002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mTOR substrate phosphorylation in growth control.
    Battaglioni S; Benjamin D; Wälchli M; Maier T; Hall MN
    Cell; 2022 May; 185(11):1814-1836. PubMed ID: 35580586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
    Hall BA; Kim TY; Skor MN; Conzen SD
    Breast Cancer Res Treat; 2012 Sep; 135(2):469-79. PubMed ID: 22842983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of insulin receptor substrate-1 by mTORC2 (mammalian target of rapamycin complex 2).
    Destefano MA; Jacinto E
    Biochem Soc Trans; 2013 Aug; 41(4):896-901. PubMed ID: 23863152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Grb10 promotes lipolysis and thermogenesis by phosphorylation-dependent feedback inhibition of mTORC1.
    Liu M; Bai J; He S; Villarreal R; Hu D; Zhang C; Yang X; Liang H; Slaga TJ; Yu Y; Zhou Z; Blenis J; Scherer PE; Dong LQ; Liu F
    Cell Metab; 2014 Jun; 19(6):967-80. PubMed ID: 24746805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanistic Target of Rapamycin Complex 1 (mTORC1) and mTORC2 as Key Signaling Intermediates in Mesenchymal Cell Activation.
    Walker NM; Belloli EA; Stuckey L; Chan KM; Lin J; Lynch W; Chang A; Mazzoni SM; Fingar DC; Lama VN
    J Biol Chem; 2016 Mar; 291(12):6262-71. PubMed ID: 26755732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling.
    Zhang C; Wendel AA; Keogh MR; Harris TE; Chen J; Coleman RA
    Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1667-72. PubMed ID: 22307628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small molecule H89 renders the phosphorylation of S6K1 and AKT resistant to mTOR inhibitors.
    Melick CH; Jewell JL
    Biochem J; 2020 May; 477(10):1847-1863. PubMed ID: 32347294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
    Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacological inhibition of S6K1 increases glucose metabolism and Akt signalling in vitro and in diet-induced obese mice.
    Shum M; Bellmann K; St-Pierre P; Marette A
    Diabetologia; 2016 Mar; 59(3):592-603. PubMed ID: 26733005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism.
    Chen CH; Kiyan V; Zhylkibayev AA; Kazyken D; Bulgakova O; Page KE; Bersimbaev RI; Spooner E; Sarbassov DD
    J Biol Chem; 2013 Sep; 288(38):27019-27030. PubMed ID: 23928304
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mTOR kinase domain phosphorylation promotes mTORC1 signaling, cell growth, and cell cycle progression.
    Ekim B; Magnuson B; Acosta-Jaquez HA; Keller JA; Feener EP; Fingar DC
    Mol Cell Biol; 2011 Jul; 31(14):2787-801. PubMed ID: 21576368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: possible involvement in obesity-linked insulin resistance.
    Khamzina L; Veilleux A; Bergeron S; Marette A
    Endocrinology; 2005 Mar; 146(3):1473-81. PubMed ID: 15604215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling.
    Woo SY; Kim DH; Jun CB; Kim YM; Haar EV; Lee SI; Hegg JW; Bandhakavi S; Griffin TJ; Kim DH
    J Biol Chem; 2007 Aug; 282(35):25604-12. PubMed ID: 17599906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
    Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
    PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disentangling the signaling pathways of mTOR complexes, mTORC1 and mTORC2, as a therapeutic target in glioblastoma.
    Jhanwar-Uniyal M; Dominguez JF; Mohan AL; Tobias ME; Gandhi CD
    Adv Biol Regul; 2022 Jan; 83():100854. PubMed ID: 34996736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
    Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
    Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.